The Scottish Medicines Consortium (SMC) has accepted tadalafil 2.5mg and 5mg tablets (Cialis®) for use in NHS Scotland for regular once-daily administration in patients with erectile dysfunction responding to an on-demand regimen of tadalafil who anticipate frequent use (at least twice weekly).

The drug advice (see link below) notes that tadalafil represents an alternative to other phosphodiesterase type 5 inhibitors, primarily for patients for whom the longer duration of action represents a significant advantage.  The low-dose regular regimen is expected to be cost-neutral compared to on-demand use at the above frequency.